1. Home
  2. BTDR vs PTCT Comparison

BTDR vs PTCT Comparison

Compare BTDR & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BTDR

Bitdeer Technologies Group

HOLD

Current Price

$10.97

Market Cap

5.5B

Sector

Technology

ML Signal

HOLD

Logo PTC Therapeutics Inc.

PTCT

PTC Therapeutics Inc.

HOLD

Current Price

$78.16

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTDR
PTCT
Founded
2021
1998
Country
Singapore
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
5.3B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
BTDR
PTCT
Price
$10.97
$78.16
Analyst Decision
Strong Buy
Buy
Analyst Count
10
17
Target Price
$28.30
$73.76
AVG Volume (30 Days)
6.7M
2.3M
Earning Date
11-10-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
8.94
Revenue
$464,436,000.00
$1,779,150,000.00
Revenue This Year
$73.71
$128.32
Revenue Next Year
$92.06
N/A
P/E Ratio
N/A
$8.79
Revenue Growth
17.40
97.54
52 Week Low
$6.84
$35.95
52 Week High
$27.80
$87.50

Technical Indicators

Market Signals
Indicator
BTDR
PTCT
Relative Strength Index (RSI) 40.56 57.21
Support Level $9.66 $73.78
Resistance Level $10.49 $76.17
Average True Range (ATR) 0.80 2.73
MACD 0.13 -0.49
Stochastic Oscillator 34.70 68.52

Price Performance

Historical Comparison
BTDR
PTCT

About BTDR Bitdeer Technologies Group

Bitdeer Technologies Group is principally engaged in provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.

About PTCT PTC Therapeutics Inc.

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.

Share on Social Networks: